Probing the mechanism of inactivation of the FOX-4 cephamycinase by avibactam
JournalAntimicrobial Agents and Chemotherapy
PublisherAmerican Society for Microbiology
MetadataShow full item record
AbstractCeftazidime-avibactam is a “second-generation” β-lactam–β-lactamase inhibitor combination that is effective against Enterobacteriaceae expressing class A extended-spectrum β-lactamases, class A carbapenemases, and/or class C cephalosporinases. Knowledge of the interactions of avibactam, a diazabicyclooctane with different β-lactamases, is required to anticipate future resistance threats. FOX family β-lactamases possess unique hydrolytic properties with a broadened substrate profile to include cephamycins, partly as a result of an isoleucine at position 346, instead of the conserved asparagine found in most AmpCs. Interestingly, a single amino acid substitution at N346 in the Citrobacter AmpC is implicated in resistance to the aztreonam-avibactam combination. In order to understand how diverse active-site topologies affect avibactam inhibition, we tested a panel of clinical Enterobacteriaceae isolates producing blaFOX using ceftazidime-avibactam, determined the biochemical parameters for inhibition using the FOX-4 variant, and probed the atomic structure of avibactam with FOX-4. Avibactam restored susceptibility to ceftazidime for most isolates producing blaFOX; two isolates, one expressing blaFOX-4 and the other producing blaFOX-5, displayed an MIC of 16 μg/ml for the combination. FOX-4 possessed a k2/K value of 1,800 ± 100 M−1 · s−1 and an off rate (koff) of 0.0013 ± 0.0003 s−1. Mass spectrometry showed that the FOX-4–avibactam complex did not undergo chemical modification for 24 h. Analysis of the crystal structure of FOX-4 with avibactam at a 1.5-Å resolution revealed a unique characteristic of this AmpC β-lactamase. Unlike in the Pseudomonas-derived cephalosporinase 1 (PDC-1)–avibactam crystal structure, interactions (e.g., hydrogen bonding) between avibactam and position I346 in FOX-4 are not evident. Furthermore, another residue is not observed to be close enough to compensate for the loss of these critical hydrogen-bonding interactions. This observation supports findings from the inhibition analysis of FOX-4; FOX-4 possessed the highest Kd (dissociation constant) value (1,600 nM) for avibactam compared to other AmpCs (7 to 660 nM). Medicinal chemists must consider the properties of extended-spectrum AmpCs, such as the FOX β-lactamases, for the design of future diazabicyclooctanes. Copyright 2018 American Society for Microbiology. All Rights Reserved.
SponsorsThese studies were partly supported by the Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, a Hofstra University Faculty Research and Development Grant, Nurses Organization of Veterans Affairs BX001974,BX002872,Foundation for the National Institutes of Health R01AI072219,R01AI100560,R01AI063517,U19-AI109713-SRP,R21AI114508, VA VISN 10.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046022774&doi=10.1128%2fAAC.02371-17&partnerID=40&md5=91cd124e69d4b27d236cc588f750b434; http://hdl.handle.net/10713/9423
- Ceftazidime-Avibactam Resistance Mediated by the N(346)Y Substitution in Various AmpC β-Lactamases.
- Authors: Compain F, Debray A, Adjadj P, Dorchêne D, Arthur M
- Issue date: 2020 May 21
- Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.
- Authors: Papp-Wallace KM, Winkler ML, Gatta JA, Taracila MA, Chilakala S, Xu Y, Johnson JK, Bonomo RA
- Issue date: 2014 Aug
- Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
- Authors: Winkler ML, Papp-Wallace KM, Bonomo RA
- Issue date: 2015 Aug
- Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
- Authors: Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA
- Issue date: 2015 Jul
- Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
- Authors: Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF
- Issue date: 2016 May